Acute Lymphoblastic Leukemia Therapeutics
1. Arranon patent expiration
Treatment: Treatment of patients with t-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens; Treatment of patients with t-ce...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5747472 | SANDOZ | Therapeutic methods for using ARA-G derivatives |
Feb, 2013
(12 years ago) | |
| US5424295 | SANDOZ | 9-β-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine |
Jun, 2017
(8 years ago) | |
| US5492897 | SANDOZ | Method for treating T-cell lymphoblastic leukemia with ara-G nucleoside derivatives |
Feb, 2013
(12 years ago) | |
| US5821236 | SANDOZ | Tumor treatment with arabinofuranosyl purine derivatives |
Feb, 2013
(12 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 28, 2012 |
Drugs and Companies using NELARABINE ingredient
Market Authorisation Date: 28 October, 2005
Dosage: INJECTABLE
More Information on Dosage
ARRANON family patents
2. Clolar patent expiration
Treatment: Clolar is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5661136 | GENZYME | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
Jan, 2018
(7 years ago) | |
|
US5661136 (Pediatric) | GENZYME | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
Jul, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 28, 2011 |
| Pediatric Exclusivity(PED) | Jun 28, 2012 |
Drugs and Companies using CLOFARABINE ingredient
Market Authorisation Date: 28 December, 2004
Dosage: SOLUTION
How can I launch a generic of CLOLAR before it's drug patent expiration?
More Information on Dosage
CLOLAR family patents
3. Iclusig patent
expiration
Treatment: A method for treating acute lymphoblastic leukemia; A method for treating chronic myeloid leukemia; A method for treating philadelphia chrom...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9493470 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(7 years from now) | |
| US11384086 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(7 years from now) | |
| US11192897 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(7 years from now) | |
| US8114874 | TAKEDA PHARMS USA | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors |
Jan, 2027
(1 year, 15 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9029533 | TAKEDA PHARMS USA | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors |
Dec, 2026
(11 months from now) | |
| US11192895 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 14, 2019 |
| Orphan Drug Exclusivity(ODE-35) | Dec 14, 2019 |
| New Indication(I-849) | Dec 18, 2023 |
| New Indication(I-934) | Mar 19, 2027 |
| Orphan Drug Exclusivity(ODE-472) | Mar 19, 2031 |
Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 18 December, 2020
Dosage: TABLET
How can I launch a generic of ICLUSIG before it's drug patent expiration?
More Information on Dosage
ICLUSIG family patents
4. Sprycel patent expiration
Treatment: A method for treatment of a cancer, wherein the cancer is chronic myelogenous leukemia; A method for the treatment of cancer
SPRYCEL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7491725 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Mar, 2026
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7125875 (Pediatric) | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Oct, 2020
(5 years ago) | |
|
US7153856 (Pediatric) | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Oct, 2020
(5 years ago) | |
|
US6596746 (Pediatric) | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Dec, 2020
(5 years ago) | |
| US7125875 | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Apr, 2020
(5 years ago) | |
| US6596746 | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Jun, 2020
(5 years ago) | |
| US7153856 | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Apr, 2020
(5 years ago) | |
| US8680103 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Feb, 2025
(11 months ago) | |
|
US7491725 (Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Sep, 2026
(8 months from now) | |
|
US8680103 (Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Aug, 2025
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-120) | May 21, 2012 |
| Orphan Drug Exclusivity(ODE) | Jun 28, 2013 |
| M(M-94) | Oct 28, 2013 |
| New Patient Population(NPP) | Nov 09, 2020 |
| New Indication(I-791) | Dec 21, 2021 |
| Orphan Drug Exclusivity(ODE-164) | Nov 09, 2024 |
| Orphan Drug Exclusivity(ODE-225) | Dec 21, 2025 |
| Pediatric Exclusivity(PED) | Jun 21, 2026 |
Drugs and Companies using DASATINIB ingredient
Market Authorisation Date: 28 June, 2006
Dosage: TABLET
How can I launch a generic of SPRYCEL before it's drug patent expiration?
More Information on Dosage
SPRYCEL family patents